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Therapy responseAbstract Objective: To detect accuracy of PET/CT in the initial staging, response after the ﬁrst
line and end of treatment in early mediastinal lymphoma patients compared to contrast CT.
Materials and methods: We studied 50 patients with pathologically proven lymphoma with a mean
age = 27.5. All patients were at early stage. All patients performed CT and PET/CT for initial
staging, after the ﬁrst course of chemotherapy (after 4–6 weeks) and at the end of treatment (after
2–4 months).
Results: PET/CT upstaged 5 cases. At ﬁrst line of treatment, PET/CT and CECT were agreeable in
32% of cases. PET/CT showed 100% sensitivity, 96.7% speciﬁcity, 95% positive predictive value
and 100% negative predictive value. At the end of treatment both methods showed a 46% agree-
ment. PET/CT was statistically signiﬁcant in the follow up of hilar and axillary lymph nodes.
PET/CT showed 100% sensitivity and speciﬁcity; compared to 62.5% sensitivity and 97.6% spec-
iﬁcity for CECT in detection of extra-nodal disease sites.
Conclusion: PET/CT proved higher sensitivity and speciﬁcity over CECT. The major strength of
PET/CT over CECT was its higher ability for detection of extra-nodal sites of lymphoma and
excluding active disease in residual nodal mass lesions on follow up.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Lymphoma is the most common primary hematopoietic malig-
nancy (1). Lymphoma comprises a histological heterogeneous
group of cancers derived from the cells of the immune system.
The hallmark of the disease is the enlargement and prolifera-
tion of lymph nodes or secondary lymphoid tissues. Both
NHL and Hodgkin’s disease may also arise from or involve
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is observed in about 70–85% of Hodgkin’s disease patients and
in 25–50% of those with Non Hodgkin’s lymphoma (3). In
early stage HL more than 90% are cured however they have
a reduced life expectancy from long term adverse events. These
include heart and lung disease and secondary malignancy (4).
Risk adapted therapy by reducing the cycles of chemotherapy
or omitting radiotherapy according to mid-treatment PET/CT
is still under trial (5).
FDG PET has been widely used for staging of disease,
detection of recurrence, and monitoring of treatment response
in patients with Hodgkin’s disease and NHL. In the past, the
imaging evaluation and follow-up of lymphoma patients were
based solely on ﬁndings at contrast-enhanced CT. However,
contrast-enhanced CT has limited sensitivity in detecting lym-
phomatous involvement of normal-sized lymph nodes, bone
marrow, spleen, and extra-nodal tissues (6,7). The residual
lymph node mass was a commonly encountered diagnostic
challenge because it is difﬁcult at CT to differentiate post-
treatment ﬁbrosis from residual viable malignant changes.
PET studies show a high sensitivity for tumor detection and
add important functional information to the inherent ana-
tomic data provided with CT. PET/CT scanning allows the
investigator to visualize and measure the intensity of residual
metabolic activity within a lesion as well as estimating its size
(6). Hodgkin’s lymphoma is FDG avid, and PET/CT is a more
accurate initial staging examination than conventional diag-
nostic CT, particularly for the detection of unexpected sites
of extranodal lymphoma (7).
In a recent systematic review, the overall sensitivity and
speciﬁcity of FDG PET/CT for initial staging of NHL and
Hodgkin’s disease were 97% and 100%, respectively (8). There
is already a considerable literature on the use of FDG-PET
and FDG-PET/CT in primary staging of lymphoma (9,10).
However limited literature on the use of FDG-PET/CT evalu-
ating the response to ﬁrst line of treatment and follow up after
the end to treatment was found, especially in cases of early
stage mediastinal lymphoma.
Our aim was to show the accuracy and contribution of
PET/CT in the initial staging, response after the ﬁrst line of
treatment and at the end of treatment in early mediastinal lym-
phoma patients in comparison to contrast enhanced CT
(CECT) study.
2. Materials and methods
We studied 50 patients with pathologically proven lymphoma
from April 2011 to July 2013. Their ages ranged from 2 up to
80 years (mean age = 27.5), including 25 males and 25 fe-
males. Exclusion criteria were diabetes mellitus and pregnancy.
All patients were at early stage according to the CT ﬁndings.
Histopathological diagnosis of lymphoma was established in
all cases after biopsy whether surgical or image guided. None
of the cases received any previous oncological treatment.
The following clinical data were obtained from all patients:
sex, age, clinical stage, extranodal involvement, presence of B
symptoms, bulky disease (tumor >10 cm and/or mediastinal
bulk >1/3 of thoracic diameter), histologic subtype according
to the WHO classiﬁcation, albumin, and erythrocyte sedimen-
tation rate (ESR), hemoglobin, leukocyte count and lympho-
cyte count.All patients included in the study performed CT and PET/
CT for initial staging, after the ﬁrst course of chemotherapy
(after 4–6 weeks) and after the end of treatment (after
2–4 months).
Staging was deﬁned according to the Ann Arbor staging
system. Treatment of early-stage disease was given according
to the Nordic Lymphoma Group protocols (11). The ﬁrst line
of treatment was ABVD (adrifmycin, bleomycin, vinblastine,
dacarbazine) in standard doses every 2 weeks (one cycle =
4 weeks) with dose modiﬁcation, granulocyte stimulation, or
delays depending on blood counts with or without local radio-
therapy. Response of treatment was assessed according to the
International Harmonization Project Criteria for Assessment
of Response to Therapy for Lymphoma (12). The study was
approved from the ethics committee in our University and
informed written consents were taken.3. Imaging protocol
FDG PET/CT scans were performed with integrated PET/CT
scanners (Biograph 16, Siemens Medical Solutions, or
Discovery 690, GE Healthcare, Waukesha, Wis). Blood
glucose levels were recorded prior to FDG injection in all pa-
tients. Patients were instructed to fast for at least 6 h prior to
the administration of FDG to decrease physiologic blood glu-
cose levels and to reduce serum insulin levels to near baseline.
Patients were not premedicated with muscle relaxants or
sedated. 18F-FDG (0.21 mCi/kg of body weight [7.78 MBq/
kg]) was injected intravenously 45–90 min prior to image
acquisition, and patients were asked to void their urine imme-
diately before the PET/CT scan. Oral contrast material was
not administered.
Once patients were positioned in the scanner, 125 ml of io-
hexol (Omnipaque 240 or 300; GE Healthcare, Princeton, NJ)
was injected intravenously at a ﬂow rate of 4 mU/s. PET and
low-dose CT images (20–120 mAs) in the whole body were ob-
tained in an arms-up position with scanning times of approx-
imately 20–30 min. In all patients, emission images were
acquired for 3 min per bed position in a three-dimensional
mode. The contrast material-enhanced CT data were used
for attenuation correction of the PET emission data and also
served as a diagnostic study. PET/CT, PET, and CT images
were displayed and reconstructed in the transaxial, coronal,
and sagittal planes.4. Image analysis
All PET/CT images were analyzed at all stages. Analyses
included measurements of the maximum anteroposterior and
transverse dimensions of the mediastinal mass on axial CT
images. A lesion was classiﬁed as positive on PET if there
was focally increased FDG uptake above background that
was not explained by physiological activity and measurements
of maximum standardized uptake values of mediastinal mass
(SUVmax). The SUVmax was deﬁned as the highest activity
concentration (in megabecquerels per milliliter) within the
target tissue with respect to the injected dose per kilogram of
body weight (in megabecquerels per milliliter per kilogram
of body weight), as determined by using the standard
software of the manufacturer. While in conventional CT, size
Fig. 1 A 12 year old male with pathologically proven HL presented a large anterior mediastinal soft tissue mass lesion (a); it shows FDG
uptake in PET-CT with SUVmax 14.2 (b); 6 weeks after chemotherapy, the mass lesion shows partial regression in size on CT (c); yet with
no detectable FDG uptake denoting full metabolic response to therapy on PET/CT (d).
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pre and post treatment scans. Extranodal thoracic (alveolar,
chest wall, pleural and bone), hilar and axillary lymph node
affection were also evaluated before and after therapy. The
ﬁndings for each of these sites were graded as positive or neg-
ative for lymphomatous inﬁltration.
5. Statistical analysis
Data were statistically described in terms of range, mean ±
standard deviation (±SD), median, frequencies (number of
cases) and percentages when appropriate. Comparison of quan-
titative variables between the study groups was done using
Kruskal–Wallis analysis of variance (ANOVA) test. For com-
paring categorical data, Chi square (v2) test was performed.
Sensitivity, speciﬁcity, positive and negative predictive values,
accuracy, P value were calculated to test validity of PET/CT.
Exact test was used instead when the expected frequency is less
than 5. P values less than 0.05 were considered statistically sig-
niﬁcant. All statistical calculations were done using computer
programs Microsoft Excel 2007 (Microsoft Corporation, NY,
USA) and SPSS (Statistical Package for the Social Science;
SPSS Inc., Chicago, IL, USA) version 15 for Microsoft
Windows.
6. Results
The study included 50 patients with mediastinal lymphoma
with 27.5 mean age.
Histopathologically; we had 37 cases of Hodgkin’s lym-
phoma (74%), 12 cases of B-cell Non Hodgkin’s lymphoma
(24%) and 1 case of T-cell lymphoma (2%).6.1. In the initial staging
CT depicted 34 cases in stage I, 13 cases in stage II and 3 cases
in stage IIE. PET/CT depicted 31 cases in stage I, 2 cases in
stage IE, 11 cases in stage II, 4 cases in stage IIE and 2 cases
in stage IV. Thus, PET/CT disagreed with CT in the initial
staging of 5 cases (10%). PET/CT upstaged 2 cases from stage
I to IE, as it detected a single extra-nodal pleural site of disease
and 1 case from stage II to IIE, with PET/CT adding the pres-
ence of a single chest wall lesion. Two cases were upstaged
from stages I and II to stage IV. One of them presented with
enlarged mediastinal lymph nodes (stage I) however, PET/
CT was able to depict two areas of intense FDG uptake in
the vertebra (SUVmax 11.7) and the anterior chest wall mus-
cles (SUVmax 11.1). The other patient presented with enlarged
mediastinal and hilar lymph nodes (stage II) yet the PET/CT
depicted two pulmonary nodules (SUVmax 10.8) and a patchy
area of alveolar inﬁltration (SUVmax 3) that was pathologi-
cally proven to be parenchymal lymphoma changing the case
to stage IV.
According to size, seven patients had bulky mediastinal
lesion >10 cm in size (Fig. 1).
6.2. After the ﬁrst line of treatment (4–6 weeks)
Conventional CT revealed complete regression in only 7
cases (14%), partial regression in 31 cases (62%) and station-
ary course in 12 cases (24%). PET/CT revealed complete
regression in 30 cases (60%), partial regression in 11 cases
(22%), progression of the disease in 7 cases (14%), stationary
course in one case (2%) and mixed response to treatment was
detected in 1 case (2%) where increased metabolic
Fig. 2 PET/CT in a 60 year old female patient with HL showing multiple enlarged mediastinal lymph nodes (a) with hypermetabolic
lymph nodes in both axillary regions (SUVmax = 4.6) (b), Biopsy was taken from the axillary lymph nodes and histology revealed
reactive inﬂammatory cells denoting false positive result by PET-CT.
Table 1 Comparison between PET-CT and CT results in treatment response after the ﬁrst course of chemotherapy.
Disease response in PET-CT Disease response in CECT
Complete regression Partial regression Stationary
Complete regression 30
60%
6
12%
19
38%
5
10%
Mixed response 1
2%
0
0%
1
2%
0
0%
Partial regression 11
22%
0
0%
9
18%
2
4%
Progressive 7
14%
1
2%
2
4%
4
8%
Stationary 1
2%
0
0%
0
0%
1
2%
Total 50
100%
7
14%
31
62%
12
24%
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was detected, the pathology-however- revealed reactive
inﬂammatory tissue and it was assigned as a PET/CT false
positive result (Fig. 2) (Table 1).
Both methods (PET/CT and CT) were agreeable in 32% of
cases (12% of cases showing complete regression, 18% show-
ing partial regression and 2% showing stationary course).
CECT was true positive in 18 cases, true negative in 6 cases,
false positive in 25 cases and false negative in 1 case showing a
94.7% sensitivity, 19.4% speciﬁcity, 41.8% positive predictive
value and 85.7% negative predictive value. PET/CT was true
positive in 19 cases, true negative in 30 cases, false positive
in 1 case and shows no false negative results with a 100% sen-
sitivity, 96.7% speciﬁcity, 95% positive predictive value and
100% negative predictive value.
6.3. After the end of chemotherapy (2–4 months)
We divided the patients into two groups, group I represents
patients with complete regression of the disease after the ﬁrst
course of chemotherapy (30 patients) and group II represents
patients (20 patients) with partial regression, stationary or pro-
gressive disease course.
In group I: 29 cases (96.7%) continued to show complete
metabolic regression on PET/CT, conventional CT agreed in
12 cases (40%), while in 8 cases (27%) it shows stationary sizeand in the other 9 cases (30%) it shows partial regression in
size of the lesions. Only one case (3%) showed a newly devel-
oped small soft tissue extra-nodal lesion involving the pleura
with SUVmax = 18.4 denoting disease relapse by PET/CT
which was conﬁrmed by biopsy and histopathology (Fig. 3).
This case was misdiagnosed as stationary by CT. Both PET/
CT and CT showed 40% agreement (Table 2).
In group II: 14 cases (70%) show complete regression with
PET/CT, conventional CT agreed in only 6 cases (25%) while
it shows 4 cases with partial regression (20%) and 4 other cases
stationary (20%). Both CT and PET/CT agreed that two cases
show partial regression (10%). 4 cases (20%) where stationary
in PET/CT, CT agreed in 3 of them (15%) and showed partial
regression in the last one (5%). Both methods agreed in 55%
of the cases and disagreed in 45% of cases (Table 3).
Thus, in both groups the agreement was in only 23 cases
representing 46%.
In general, the mean SUVmax estimated in the initial study
in mediastinal lymphoma cases was 12, after the ﬁrst course of
chemotherapy, the median SUVmax was 3.1, at the end of
treatment, the median SUVmax was 1.3.
In mediastinal HL speciﬁcally; the mean SUVmax was 11.3,
2.9 and 0.5 in the initial, ﬁrst follow up and second follow up
study respectively while, cases of mediastinal B cell NHL
showed mean SUVmax of 14.2 in the initial study, 5.5 in the
ﬁrst follow up and 3 in the second follow up study.
Fig. 3 A 26 year old female patient with NHL. CECT (a) shows a pleural nodule. PET-CT (b) shows a 4 · 3 cm soft tissue lesion
attached to the pleura of the right upper lobe with estimated SUVmax = 18.4 denoting extra-nodal pleural disease.
Table 2 Comparison between PET-CT and CT results in Group I after the end of treatment.
Disease response in PET-CT Disease response in CECT
Complete regression Partial regression Stationary
Complete regression 29
96.7%
12
40%
9
30%
8
27%
Disease relapse 1
3%
0
0%
0
0%
1
3%
Total 30
100%
12
40%
9
30%
9
30%
Table 3 Comparison between PET-CT and CT results in Group I after the end of treatment.
Disease response in PET-CT Disease response in CECT
Complete regression Partial regression Stationary
Complete regression 14
70%
6
30%
4
20%
4
20%
Partial regression 2
10%
0
0%
2
10%
0
0%
Stationary 4
20%
0
0%
1
5%
3
15%
Total 20
100%
6
30%
7
35%
7
35%
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Eleven cases had associated enlarged hilar lymph nodes. PET/
CT showed complete regression in 8 cases (72.7%) of which
CT agreed in 5 cases and showed partial regression in the
other three. One case showed partial regression on PET/CT
which was diagnosed as stationary course according to the
CT ﬁndings. The last case showed stationary course in both
methods.
We had 6 cases associated with axillary lymph nodes. PET/
CT showed complete regression in 4 cases, partial regression in
one case and progressive course in the last case. CT showed
complete regression in 2 cases, partial regression in 4 cases,
thus agreeing with PET/CT in 3 cases (50%).
6.5. Extra-nodal sites
We detected 10 cases with extra-nodal sites of thoracic
lymphoma disease in our study; 5 cases had pathologically
proven alveolar pulmonary inﬁltration (nodules or area ofconsolidation) (Fig. 4) pleural lymphomatous lesions
(n= 2) and chest wall lesions (n= 2), bony lesion in the ster-
num (n= 1).
The estimated SUVmax in extranodal lymphoma was 8.8,
3.7 and 4.4 at initial study, after the ﬁrst course of chemother-
apy and at the end of treatment respectively. Thus PET/CT de-
tected 6 cases with complete remission, 2 had stationary
course, one with partial regression and only one case showed
progression of the disease in the 2–4 months’ follow up.
Four other cases (8%) showed tiny parenchymal nodules
detected by CT (less than 5 mm) with no activity on PET/
CT. We did not consider these nodules in the initial staging
as we thought that they were probably non-speciﬁc inﬂamma-
tory nodules. Nevertheless, lymphoma could not be totally
excluded as their metabolic activity may be too low to be de-
tected by PET/CT due to their tiny size. So, they were closely
followed up and showed stationary size with absent metabolic
activity conﬁrming their benign nature.
We found a 100% sensitivity and speciﬁcity for PET-CT;
compared to 62.5% sensitivity and 97.6% speciﬁcity for CECT
in detection of extra-nodal disease sites.
Fig. 4 Axial CECT (a) showing a large bulky mediastinal mass in a 33 year old male with Hodgkin lymphoma. PET-CT (b) shows an
estimated SUVmax of 11.2. A right upper lobe patchy area of consolidation was also noted with SUVmax of 3 (arrow); 4 weeks after
chemotherapy the CT shows regression in the size of the anterior mediastinal mass lesion (c) with no evidence of hyper metabolism in
PET-CT denoting complete metabolic response in spite of partial regression in size. The consolidated lesion also showed complete
response (d).
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low up of mediastinal hilar lymph nodes. It also shows statis-
tical signiﬁcance in the follow up of axillary lymph nodes
(P= 0.046).
7. Discussion
CT is the most readily available and most commonly used tool
for staging lymphoma. Fundamental limitations of CT are that
recognition of lymph node involvement is based solely on size
and that detection of bone marrow and extra-nodal tissue
involvement may be limited. In addition to depicting nodal
sites of lymphoma with greater accuracy than CT, PET/CT
can detect the activity of the lesion and has greater sensitivity
for sites of extra-nodal involvement and correspondingly has
been found to improve baseline staging compared with con-
ventional staging with CT alone (13). Hodgkin’s lymphoma
is FDG avid, and PET/CT is more accurate in initial staging
than CECT.
In this study PET/CT upstaged 5 cases (10%). PET/CT and
CT were concordant in staging of the other 45 cases (90%).
The concordant in staging in our study between PET/CT
and CT was higher than that detected by Riad et al. They
found a 73.2% concordance (14). Although it was agreeable
with Pelosi et al. who found a 12% upstaging by PET/CT com-
pared to CT (15) the additional value of PET/CT causing
upstaging in our cases was not in detecting active subcentimet-
ric lymph nodes as in the study conducted by Ranani et al. (16)
but in detecting the extra-nodal thoracic sites of disease that
were not determined by CECT. Downstaging of cases was
documented in previous studies (15,16), as they detected
enlarged lymph nodes by CT yet, not metabically active onPET/CT. No similar cases that needed downstaging were
found in our study because our patients had early stage
lymphoma disease.
An important and valid application of PET/CT is to detect
viable tumor in residual lesions after the treatment of patients
with HL and NHL. A residual mass at the end of therapy is
not a rare ﬁnding and is considered a clinical challenge in
HL and intermediate/high grade NHL restaging. FDG-PET
has proved to be much more accurate in distinguishing ﬁbrosis
from viable tumor, since ﬁbrosis does not show high metabolic
activity in contrast to viable residual tumor (Figs. 1 and 4)
(17). This fact made FDG PET/CT extremely useful for ther-
apy response assessment.
Our study conﬁrmed the value of PET/CT in initial staging
and planning that involved ﬁeld radiotherapy. We showed that
PET/CT detected a 60% complete regression ratio compared
to only 14% by CT scan. In the future this may be relied upon
to minimize chemotherapy cycles in favorable group of pa-
tients, hence reducing the side effects of treatment (5).
A bulky mediastinal mass is often seen in patients with
Hodgkin’s lymphoma. Treatment of Hodgkin’s lymphoma of-
ten results in size reduction of the mass, but complete disap-
pearance of the mass is unusual. Detection of viable tumor
in these residual masses is difﬁcult with conventional imaging
modalities (1). We had seven cases with bulky mediastinal
masses (>10 cm). All of them showed a signiﬁcant decrease
in size by CT scan, while PET/CT showed complete regression
of the disease with no evident activity denoting ﬁbrosis in four
cases (Figs. 1 and 4). In one case it showed partial progression
and in the last two cases PET/CT detected progressive course
of the disease despite the considerable reduction in size of the
mass lesion.
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CT after the ﬁrst line of treatment of mediastinal lymphoma
which was comparable to previous studies (8,18).
In the second follow up study after the end of chemother-
apy cycles, PET/CT and CECT were concurrent in results in
22 cases (44%) and discordant in 28 cases (56%) in contradic-
tion to Zinzani et al. who showed much higher agreement per-
centage between both modalities (90%) and less disagreement
(19).
In the study conducted by Ranani et al. few cases with pul-
monary lesions interpreted as benign by the CT scan were read
as lymphomatous inﬁltration on PET/CT (16). In our study,
we reported 5 cases (10%) presenting with pulmonary disease
at the time of initial diagnosis, all showed parenchymal lung
nodules ranging between 2 and 4 cm in diameter on CT with
patchy areas of consolidation. PET/CT showed positive activ-
ity with SUVmax ranging from 4.3 to 11.6 (mean SUV-
max = 8), which was conﬁrmed by CT guided biopsy as
active lymphocytic alveolar inﬁltration. The other four cases
with tiny parenchymal nodules detected by CT, that did not
show activity on PET/CT were conﬁrmed as benign by further
follow up.
Axillary lymph node enlargement is usually nonspeciﬁc,
however if associated with other pathological localizations it
shows true positive results in most cases and is an indicator
of high likelihood of disease recurrence (20). We had only four
cases with associated axillary lymph node that showed a signif-
icant P value on PET/CT follow up.
Several studies compared CECT to PET/CT in detection of
extra-nodal lymphoma; all were around 88% sensitivity and
100% speciﬁcity for PET-CT compared to 50% sensitivity
and 90% speciﬁcity with CECT (6,18,21). We reported 100%
sensitivity and speciﬁcity for PET-CT; compared to 62.5%
sensitivity and 97.6% speciﬁcity for CECT in detection of ex-
tra-nodal disease sites.
Our study was limited by the absence of further follow up
of the patients after 6 mo-2 years to detect the overall survival
and time to progression to disease.
PET/CT proved higher sensitivity and speciﬁcity over
CECT in our study. The major strength of PET/CT over
CECT was its higher ability for detection of extra-nodal sites
of lymphoma at initial staging and its much higher ability to
exclude active disease in residual nodal mass lesions on follow
up studies. The use of early response to therapy of lymphoma
patients by PET/CT may tailor the dose of chemotherapy
avoiding unnecessarily toxic treatment.
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